Variation in Gingival Inflammatory Responses

Inclusion Criteria:

* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for the duration of the study
* Male or female, aged 18-35 years
* Good general health, ASA I (healthy with no systemic conditions)
* No clinical signs of gingival inflammation at \> 90% of sites observed (whole mouth) (\< 10% of sites with GI of \< 2 and no sites with a score of 3; \< 10% sites with BOP +).
* Probing depth (PD) ≤ 3.0 mm (Whole Mouth)
* Attachment loss (AL) = 0 mm (Whole Mouth)
* Gingival health at Visit 2 (Day 0) for study sites (Test/Control teeth): Average Gingival Index (GI) ≤ 0.1 with no site having a score of 3 and bleeding on probing (BOP)(-)
* Never smokers
* The ability to understand and communicate with the examiner.
* Willing and able to comply with study procedures.

Exclusion Criteria:

* Medical condition which requires premedication prior to dental treatments/visits
* Subjects unable or unwilling to sign the informed consent form
* History of periodontal disease
* History of systemic inflammatory or immune conditions, Diabetes
* Use of antibiotic or anti-inflammatory drugs within 30 days of enrollment
* Self-reported pregnancy, planned pregnancy during the planned study commitment, and/or breastfeeding at the time of screening.
* Concurrent orthodontic treatment
* Untreated carious lesions and/or inadequate restorations on maxillary posterior teeth
* Participation in any other clinical study or test panel within 1 week prior to enrollment into this study
* Use of tobacco products
* Subjects who must receive dental treatment during the study dates
* Orthodontic bands, appliances, or crowns and bridges, or removable partial dentures affecting the maxillary posterior teeth
* Missing tooth/teeth within the study sites test and control
* History of allergy to common dentifrice ingredients
* Immune-compromised individuals (for example: HIV, AIDS, and immune-suppressive drug therapy)